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Aims. We sought to investigate whether enhanced oxidation contributes to unfavorable fibrin clot properties in patients with
diabetes.Methods. We assessed plasma fibrin clot permeation (𝐾
𝑠
, a measure of the pore size in fibrin networks) and clot lysis time
induced by recombinant tissue plasminogen activator (CLT) in 163 consecutive type 2 diabetic patients (92 men and 71 women)
aged 65 ± 8.8 years with a mean glycated hemoglobin (HbA1c) of 6.8%. We also measured oxidative stress markers, including
nitrotyrosine, the soluble form of receptor for advanced glycation end products (sRAGE), 8-iso-prostaglandin F
2𝛼
(8-iso-PGF
2𝛼
),
oxidized low-density lipoprotein (oxLDL), and advanced glycation end products (AGE). Results. There were inverse correlations
between𝐾
𝑠
and nitrotyrosine, sRAGE, 8-iso-PGF
2𝛼
, and oxLDL. CLT showed a positive correlation with oxLDL and nitrotyrosine
but not with other oxidation markers. All these associations remained significant for 𝐾
𝑠
after adjustment for fibrinogen, disease
duration, and HbA1c (all 𝑃 < 0.05), while oxLDL was the only independent predictor of CLT. Conclusions. Our study shows that
enhanced oxidative stress adversely affects plasma fibrin clot properties in type 2 diabetic patients, regardless of disease duration
and glycemia control.
1. Introduction
There is compelling evidence that type 2 diabetes (T2DM)
is associated with a prothrombotic state including increased
thrombin generation and platelet hyperactivity as well as
endothelial dysfunction [1–3]. Higher plasma D-dimer levels
in diabetic patients were also observed in several studies [4].
The structure of a fibrin clot, the final step of blood coag-
ulation, has shown to be influenced by both genetic and
environmental factors [5]. A number of studies have demon-
strated that the structure and function of fibrin clots are
unfavorably altered in subjects with T2DM [5, 6]. Fibrin
clots made from plasma of diabetic subjects have a denser,
less porous structure than those formed from control plasma
and they are more resistant to fibrinolysis [5]. Similar find-
ings have been reported in studies performed on purified
fibrinogen obtained from diabetic patients at various levels
of metabolic control [7]. Denser fibrin networks have been
shown to be related to worse glycemic control, reflected by
elevated glycated hemoglobin (HbA1c). Glycation of fibrino-
gen may interfere with fibrin polymerization, cross-linking
by FXIII, tissue plasminogen activator (tPA), plasminogen
binding, and plasminogen to plasmin conversion [6]. How-
ever, it has also been demonstrated that, in some diabetic
patients as compared to controls, there are no differences in
clot permeability despite a marked difference in fibrinogen
glycation, suggesting that other potent factors contribute to
clot phenotype in this disease [7]. Of note, treatment with
insulin has been shown to make fibrin more permeable
despite no improvement in glycemia control [8]. Recently,
it has been demonstrated that glycation of plasminogen also
contributes to impaired fibrinolysis in T2DM [9].
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Decreased clot susceptibility to fibrinolysis, together with
high levels of plasminogen activator inhibitor-1 (PAI-1),
which is typical of T2DM [10] and associated with abdominal
obesity [5], may contribute to an increased atherothrombotic
risk in this disease. Clinical relevance of resistance to lysis has
been reinforced by observations indicating that T2DM pre-
dicts the failure of thrombolytic therapy in patients with acute
myocardial infarction [11]. Recently, we have demonstrated
that, even in patients with good glycemia control, prolonged
duration of T2DM is associated with impaired fibrinolysis
and formation of more compact fibrin clots [12].
Growing evidence indicates that enhanced oxidative
stress is implicated in the pathogenesis of diabetes [13]. Ele-
vated levels of 8-iso-prostaglandin F
2𝛼
(8-iso-PGF
2𝛼
), an iso-
prostane that is produced by the nonenzymatic peroxidation
of arachidonic acid in patients with T2DM, are detected
in 24-hour urinary samples [14]. Moreover, acute glucose
fluctuations were correlated with urinary excretion of 8-
iso-PGF
2𝛼
[14, 15]. High serum peroxynitrite levels have
been shown in diabetic patients by Al-Nimer et al. [16].
Elevated levels of circulating oxidized low-density lipoprotein
(oxLDL), another oxidation marker, have also been demon-
strated in patients with T2DM [17, 18]. Free radicals are
formed disproportionately by glucose oxidation, nonenzy-
matic glycation of proteins, and the subsequent oxidative
degradation of glycated proteins. High levels of free radicals
and the simultaneous decline of antioxidant defense can lead
to increased lipid peroxidation and insulin resistance [19].
Oxidative modifications in the fibrinogen molecules can also
alter the clot structure. Fibrin deposits formed in the presence
of ferric ions are remarkably resistant to proteolytic and
chemical degradations. Fibrinogenmodification can alter the
rate of assembly of fibrin monomers into a fibrin clot and the
fibrin structure [20, 21]. Associations between plasma fibrin
clot properties and increased oxidative stress, reflected by
plasma levels of 8-iso-PGF
2𝛼
, have been reported in patients
with acute myocardial infarction [22] and in heavy cigarette
smokers [23]. It is unknownwhether oxidative stressmodifies
fibrin clot characteristics in diabetes. Since T2DM markedly
alters fibrin clot structure and enhances clot resistance to fib-
rinolysis that might predispose to cardiovascular thrombotic
complications, elucidation of mechanisms underlying these
abnormalities is of utmost importance. We hypothesized that
increased oxidation contributes to altered plasma fibrin clot
properties in T2DM.
2. Material and Methods
2.1. Subjects. We enrolled 163 consecutive white patients with
T2DM diagnosed based on the WHO criteria. The exclusion
criteria were as follows: signs of acute infection, known
cancer, chronic inflammatory disease, liver injury (alanine
and aspartate transaminase >1.5 times above the upper limit
of the reference range), estimated glomerular filtration rate
(eGFR) <30mL/min, pregnancy, arterial or venous throm-
boembolic events within the previous 6 months, and current
anticoagulant therapy, all the states known to substantially
alter blood coagulation or fibrin clot structure [24].
Demographic and clinical data were collected using a
standardized questionnaire. Dyslipidemia was defined as
total cholesterol (TC) >5.0mmol/L, low-density lipopro-
tein (LDL) cholesterol >2.6mmol/L, and triglycerides (TG)
>1.7mmol/L or ongoing lipid-lowering treatment. Obesity
was defined as the body mass index (BMI) >30 kg/m2. Coro-
nary artery disease (CAD) was diagnosed based on positive
results of cardiac stress test, cardiac catheterization, or coro-
nary computed tomography angiogram. Peripheral artery
disease (PAD) was defined based on the ankle-brachial index
(ABI) <0.9. Previous myocardial infarction (MI), ischemic
stroke, or revascularization was established based onmedical
records. Diabetic nephropathy was defined as macroalbu-
minuria (albumin to creatinine ratio [ACR] >34mg/mmol
[300mg/g]) or microalbuminuria (ACR 3.4 to 34mg/mmol
[30–300mg/g]) associated with retinopathy. Diabetic neu-
ropathy was diagnosed according to the Toronto Diabetic
Neuropathy Expert Group definition [25]. Diabetic retinopa-
thy was diagnosed by an independent ophthalmologist.
The local ethics committee approved the study. All
enrolled subjects provided a written informed consent.
2.2. LaboratoryMethods. Bloodwas drawn after an overnight
fast from an antecubital vein. Lipid profile, glucose, creati-
nine, blood cell, and platelet counts were assayed by routine
laboratory techniques. To obtain plasma, blood samples were
mixed with 3.2% sodium citrate (9 : 1) centrifuged once for
20min and stored at −80∘C. HbA1c and high sensitivity C-
reactive protein (CRP) were measured using immunotur-
bidimetric methods (Roche Diagnostics GmbH, Mannheim,
Germany). Fibrinogen was determined with the von Clauss
method.
We measured using commercially available enzyme-
linked immunosorbent assays (ELISA) the following oxi-
dation markers: nitrotyrosine (Millipore, USA), advanced
glycation end products (sRAGE) (R&D Systems, Minneapo-
lis, MN, USA), serum 8-iso-PGF
2𝛼
(Cayman Chemicals,
Ann Arbor, MI), and serum oxLDL (Mercodia AB, Upp-
sala, Sweden). To assess the advanced glycation end prod-
uct (AGE) concentration, plasma fluorescence spectra were
recorded with Fluoroskan Ascent FL, Labsystems (excita-
tion 355 nm/emission 460 nm). AGE measurements were
expressed in arbitral units (U/mL). This method measures
a combination of glycation and oxidation products such as
pentosidine, cross links, and others. Total serum fluorescence
in humans is associated mainly with high molecular mass
proteins, particularly albumin [26].
2.3. Clot Fibrin Variables. To perform fibrin clot analysis,
venous blood samples were collected (vol/vol, 9 : 1) into 3.2%
trisodium citrate. Plasma samples were centrifuged at 2560 g
within 20 minutes of collection, immediately frozen, and
stored in aliquots at −80∘C until further use. Plasma fibrin
clot variables were determined in duplicate by technicians
not familiar with the origin of samples (intra-assay and
interassay coefficients of variation, <8%), as described with
slight modifications [12, 27].
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Fibrin clot permeation was assessed using a pressure-
driven system, with calculation of a permeation coefficient
(𝐾
𝑠
), using the following equation:
𝐾
𝑠
=
𝑄 ⋅ 𝐿 ⋅ 𝜂
𝑡 ⋅ 𝐴 ⋅ Δ𝑝
, (1)
where 𝑄 is the flow rate in time 𝑡, 𝐿 is the length of a
fibrin gel, 𝜂 is the viscosity of liquid (in poise), 𝐴 is the
cross-sectional area (in cm2), Δ𝑝 is a differential pressure (in
dyne/cm2), and 𝑡 is percolating time. Lower𝐾
𝑠
values indicate
reduced permeability. Briefly, 100 𝜇L of citrated plasma was
mixed with 20𝜇L of a reagent mixture at final concentrations
of 10 pmol/L TF (Innovin, Siemens Healthcare Diagnos-
tics, Marburg, Germany), 4 𝜇mol/L phospholipids (Rossix,
Mölndal, Sweden) and 20mmol/L CaCl
2
. The mixture was
immediately moved to the mechanically scratched tubes.
Then the gel was stabilized for 2 hours in a moisture chamber
at room temperature. The tubes were connected via silicone
tube to a reservoir containing Tris-buffered saline (TBS,
50mmol/L Tris-HCl and 0.1mol/L NaCl, pH 7.4), with a
pressure drop of 4 cmH
2
O.After washing, flow rates of buffer
through the clots were measured.
Clot lysis time (CLT) was measured using a tissue factor-
induced clot lysis assay. Briefly, citrated plasma was mixed
with calcium chloride at final concentration of 15mmol/L,
human tissue factor (Innovin, Dade Behring, Marburg,
Germany) at final concentration of 0.6 pmol/L, phospholipid
vesicles (Avanti Polar Lipids, Alabaster, AL) at a final con-
centration of 12mmol/L, and recombinant tPA (Boehringer
Ingelheim, Germany) at final concentration of 50 ng/mL.
All the dilutions were prepared in Tris buffered saline
(50mmol/L Tris-HCl, 0.1mol/L NaCl, pH 7.4). Plasma repre-
sented 50% of the mixture volume. Turbidity was measured
at 405 nm at 37∘C. CLT was defined as the time from the
midpoint of the baseline clear to maximum turbid transition,
to the final plateau phase.
2.4. Statistical Analysis. Statistical analysis was performed by
use of MedCalc for Windows, version 13.1.2.0. All the text
and tables results are expressed as mean ± standard deviation
(SD) ormedian and interquartile range (IQR) or number and
percentage. Continuous variables were compared between
groups using 𝑡-test (variables with normal distribution) or
𝑈 Mann-Whitney test (nonnormally distributed variables).
Categorical variables were compared by use of the chi-square
test. To determine the relationship between variables the
Spearman rank-order or Pearson correlations were analyzed.
Finally amultivariate regressionmodelwas constructed using
all variables, that is, oxidative markers, duration of diabetes,
HbA1c, fibrinogen, and othermarkers (if in univariate regres-
sion a 𝑃 value was <0.1) in backward approach to determine
which factors had influence after adjustment. A𝑃 value <0.05
was considered statistically significant.
3. Results
The final analysis included 163 patients (92 men and 71
women aged 65 ± 8.8 years, range 49–82 years) with
Table 1: Patient characteristics (𝑛 = 163).
Variable
Age (years) 65 ± 8.8
Male gender, 𝑛 (%) 92 (55.4)
BMI, kg/m2 31.9 ± 5.2
WHR 0.98 (0.93–1.04)
Cardiovascular risk factors, 𝑛 (%)
Obesity 109 (66.9)
Current smoker 16 (9.8)
Previous smoker 82 (50.3)
Hypertension 153 (93.9)
Dyslipidemia 126 (77.3)
Family history of CAD 40 (24.5)
Medical history, 𝑛 (%)
CAD 100 (61.3)
Previous MI 27 (16.6)
Previous PCI/CABG 2 (1.2)
Previous stroke or TIA 11 (6.7)
PAD 22 (13.5)
Nephropathy 29 (17.8)
Retinopathy 24 (14.7)
Neuropathy 33 (20.2)
Insulin therapy 43 (26.4)
Biguanide 97 (59.5)
Sulphonylurea 69 (42.3)
Aspirin 130 (79.8)
Thienopyridine 9 (5.5)
Statin 128 (78.5)
Fibrate 7 (4.3)
Beta-blocker 131 (80.4)
ACEI 117 (71.8)
Laboratory results
GFR, mL/min 78.2 ± 20.0
TC, mmol/L 4.3 (3.5–5.1)
LDL-C, mmol/L 2.4 (1.9–3.1)
HDL-C, mmol/L 1.3 (1.1–1.6)
TG, mmol/L 1.3 (1.0–1.9)
CRP, mg/L 2.2 (1.1–4.1)
Glucose, mmol/L 6.0 (5.1–7.3)
HbA1c, % 6.8 ± 1.036
Values are given as mean ± SD, median (interquartile range), or percentage.
𝑃 value was calculated using Student 𝑡-test when variables were normally
distributed or by the Mann-Whitney 𝑈-test for nonnormally distributed
variables.
Abbreviations: DM, type 2 diabetes; HbA1c, glycated hemoglobin; WHR,
waist to hip ratio; CAD, coronary artery disease; MI, myocardial infarction;
PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft; TIA, transient ischemic attack; PAD, peripheral artery disease; ACEI,
angiotensin-converting enzyme inhibitor; GFR, glomerular filtration rate;
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-
C, high-density lipoprotein cholesterol; TG, triglycerides; CRP, C-reactive
protein.
a mean duration of diabetes of 5 years and mean HbA1c
of 6.8% (Table 1). There were 127 subjects with DM dura-
tion ≤10 years and 36 with DM duration above 10 years.
Vascular manifestations of T2DM were as follows: diabetic
nephropathy 𝑛 = 29 (17.8%), diabetic retinopathy 𝑛 = 24
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Table 2: Levels of oxidation markers in specific groups.
Variables oxLDL Nitrotyrosine AGE sRAGE PGF2𝛼
ng/mL nM/mL U/mL ng/mL pg/mL
Obesity (+) 216 (185–250) 0.62 (0.59–0.70) 7.1 (6.1–8.4) 0.91 (0.85–0.98) 449 (415–480)
Obesity (−) 221 (180–273) 0.66 (0.60–0.69) 6.1 (7.1–8.1) 0.94 (0.86–0.99) 459 (406–485)
𝑃 0.56 0.24 0.51 0.50 0.32
Current smoker (+) 180 (167–233) 0.66 (0.55–0.75) 6.6 (5.9–7.7) 0.88 (0.85–1.07) 451 (360–498)
Current smoker (−) 219 (189–263) 0.63 (0.60–0.70) 6.6 (5.9–7.7) 0.92 (0.86–0.99) 453 (417–481)
𝑃 0.04 0.55 1.0 0.54 0.94
Previous smoker (+) 212 (180–250) 0.64 (0.60–0.70) 7.1 (6.0–8.4) 0.92 (0.87–0.99) 458 (418–481)
Previous smoker (−) 220 (186–260) 0.61 (0.57–0.68) 7.1 (6.3–8.3) 0.91 (0.85–0.98) 448 (410–480)
𝑃 0.61 0.05 0.98 0.38 0.20
Hypertension (+) 217 (182–255) 0.63 (0.59–0.70) 7.1 (6.1–8.4) 0.92 (0.85–0.99) 453 (417–481)
Hypertension (−) 242 (193–266) 0.67 (0.61–0.70) 6.5 (5.4–7.1) 0.91 (0.83–1.04) 458 (398–479)
𝑃 0.52 0.37 0.18 0.70 0.93
Dyslipidemia (+) 218 (186–258) 0.63 (0.60–0.69) 7.1 (6.1–8.4) 0.91 (0.85–0.99) 453 (418–480)
Dyslipidemia (−) 121 (180–253) 0.62 (0.55–0.70) 7.0 (6.3–7.8) 0.94 (0.88–0.98) 452 (401–482)
𝑃 0.72 0.70 0.44 0.82 0.81
FH (+) 214 (184–247) 0.63 (0.58–0.70) 6.9 (6.0–8.1) 0.91 (0.85–0.97) 458 (417–478)
FH (−) 219 (184–265) 0.63 (0.60–0.70) 7.1 (6.2–8.4) 0.92 (0.86–0.99) 452 (409–481)
𝑃 0.49 0.90 0.55 0.55 0.89
CAD (+) 218 (186–268) 0.63 (0.60–0.70) 7.2 (6.4–8.4) 0.92 (0.85–0.99) 457 (416–496)
CAD (−) 208 (178–250) 0.63 (0.57–0.67) 6.8 (5.9–8.1) 0.92 (0.87–0.99) 542 (413–480)
𝑃 0.44 0.22 0.14 0.58 0.17
Previous MI (+) 198 (175–235) 0.68 (0.60–0.72) 7.5 (6.5–8.4) 0.92 (0.88–0.92) 457 (416–496)
Previous MI (−) 220 (190–260) 0.62 (0.59–0.69) 7.1 (6.0–8.2) 0.91 (0.85–0.99) 452 (413–480)
𝑃 0.14 0.06 0.27 0.41 0.4
Prev. stroke/TIA (+) 198 (181–240) 0.63 (0.60–0.70) 7.4 (6.4–9.3) 0.92 (0.85–0.99) 451 (403–480)
Prev. stroke/TIA (−) 217 (185–260) 0.63 (0.57–0.67) 7.1 (6.1–8.2) 0.92 (0.87–0.99) 459 (429–491)
𝑃 0.53 0.38 0.21 0.18 0.13
PAD (+) 197 (168–280) 0.60 (0.55–0.77) 7.0 (6.1–8.2) 0.91 (0.81–0.97) 420 (389–460)
PAD (−) 218 (189–254) 0.63 (0.60–0.70) 7.1 (6.1–8.4) 0.92 (0.86–0.99) 457 (421–481)
𝑃 0.41 0.69 0.93 0.24 0.12
Nephropathy (+) 210 (179–243) 0.63 (0.60–0.71) 6.5 (5.9–7.3) 0.92 (0.90–1.01) 468 (440–501)
Nephropathy (−) 218 (186–264) 0.63 (0.59–0.70) 7.2 (6.2–8.4) 0.91 (0.85–0.99) 450 (402–478)
𝑃 0.34 0.55 0.04 0.17 0.04
Retinopathy (+) 210 (185–244) 0.60 (0.60–0.70) 7.1 (6.3–7.7) 0.91 (0.83–0.99) 445 (398–481)
Retinopathy (−) 220 (184–258) 0.63 (0.59–0.70) 7.1 (6.1–8.4) 0.92 (0.86–0.99) 453 (417–481)
𝑃 0.69 0.94 0.55 0.45 0.69
Data expressed as median interquartile range (IQR).
Abbreviations: oxLDL, oxidized low-density lipoprotein; AGE, advanced glycation end-product; sRAGE, the soluble form of receptor for advanced glycation
end products; PGF
2𝛼
, 8-iso-prostaglandin F
2𝛼
; FH, family history of diabetes; CAD, coronary artery disease; MI, previousmyocardial infarction; TIA, transient
ischemic attack; PAD, peripheral artery disease.
(14.7%), and diabetic neuropathy 𝑛 = 33 (20.2%). One hun-
dred patients had coronary artery disease. There were 114
(69.9%) patients with good glycemic control (HbA1c ≤7%)
and 49 patients (30.1%) with inadequate glycemic control
(HbA1c >7%). Forty-three (26.4%) patients were treated with
insulin, and 166 patients received oral hypoglycemic drugs
(biguanides and suphonylurea). There were more patients
treated with insulin among those with HbA1c >7%. Subjects
with HbA1c >7% like those with DM duration >10 years
had higher prevalence of obesity, hypertension, dyslipidemia,
CAD, previous MI, previous coronary interventions, PAD,
nephropathy, and retinopathy.
3.1.The Relationship between OxidationMarkers. Differences
in oxLDL levels investigated in plasma sampleswere observed
between current smokers and nonsmokers (𝑃 = 0.04). 8-
iso-PGF
2𝛼
levels were higher, while AGE levels were slightly
lower, in patients with nephropathy compared with those
without this complication (both 𝑃 = 0.04). No differences
were observed with regard to the presence of other concomi-
tant diseases (Table 2).
As expected, there were positive correlations between
AGE and oxLDL (𝑟 = 0.341, 𝑃 < 0.0001) and AGE and
nitrotyrosine (𝑟 = 0.244, 𝑃 < 0.0035) as well as between
sRAGE and 8-iso-PGF
2𝛼
(𝑟 = 0.688, 𝑃 < 0.0001) and nitroty-
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Table 3: Univariate correlations of clot permeability (𝐾
𝑠
, 10−9 cm2)
and clot lysis time (CLT, min).
𝐾
𝑠
, CLT 𝐾
𝑠
1 CLT1
HbA1c, % 𝑟 −0.30 0.14
𝑃 0.0002 0.10
DM duration 𝑟 −0.32 0.14
𝑃 0.0001 0.09
Nitrotyrosine, nM/mL 𝑟 −0.44 0.19 −0.47 0.14
𝑃 <0.001 0.02 <0.001 0.08
AGE, U/mL 𝑟 −0.20 0.107 −0.17 −0.02
𝑃 0.01 0.20 0.05 0.82
sRAGE, ng/mL 𝑟 −0.27 0.13 −0.26 0.05
𝑃 0.001 0.11 0.001 0.53
PGF
2𝛼
, pg/mL 𝑟 −0.22 0.13 −0.25 0.11
𝑃 0.007 0.10 0.003 0.19
oxLDL, ng/mL 𝑟 −0.33 0.48 −0.21 0.41
𝑃 0.0001 <0.0001 0.01 <0.0001
Glucose, mmol/L 𝑟 −0.14 0.20
𝑃 0.07 0.02
1
𝑃 after adjustment for fibrinogen, DM duration time, and HbA1c.
Abbreviations: see Tables 1 and 2.
rosine (𝑟 = 0.694, 𝑃 < 0.0001). 8-iso-PGF
2𝛼
was also corre-
lated with nitrotyrosine (𝑟 = 0.5, 𝑃 < 0.0001) and oxLDL
with nitrotyrosine (𝑟 = 0.218, 𝑃 < 0.009). Fasting glucose
correlated with 8-iso-PGF
2𝛼
(𝑃 = 0.03) but not with other
oxidation parameters. In contrast, HbA1c positively corre-
lated with nitrotyrosine (𝑃 = 0.006) and oxLDL (𝑃 = 0.02).
There were no correlations between disease duration and
oxidation markers (data not shown).
3.2. Fibrin Clot Properties and Its Relationship to Oxidation
Markers. As expected, 𝐾
𝑠
and CLT investigated in vitro in
plasma samples were inversely correlated in diabetic patients
(𝑟 = −0.5, 𝑃 < 0.0001). We found inverse correlations
between 𝐾
𝑠
and both diabetes duration (𝑟 = −0.32, 𝑃 =
0.0001) and HbA1c (𝑟 = −0.30, 𝑃 = 0.0001) in the whole
group. No similar associations were observed for CLT
(Table 3). There were no associations between lipid profile or
renal function and fibrin properties (data not shown).
Importantly, there were inverse correlations between 𝐾
𝑠
and all the 5 oxidationmarkers, that is, nitrotyrosine, sRAGE,
8-iso-PGF
2𝛼
, AGE, and oxLDL (Table 3). There were also
positive correlations of CLT with oxLDL and nitrotyrosine
but not with other oxidation markers (Table 3).
Longer clot lysis time and lower clot permeability (after
adjustment for fibrinogen and HbA1c) were observed in
T2DM with longer diabetes duration. In patients with dia-
betes duration >10 years we observed prolonged CLT (mean
value 100min, 95% CI: 94.5–105.5) compared with the values
obtained for subjects with shorter history of diabetes (mean
value 93.7min, 95% CI: 90.8–96.6, 𝑃 = 0.048). Similarly
longer diabetes duration was associated with lower𝐾
𝑠
(mean
value 6.8 × 10−9 cm2, 95% CI: 6.5–7.0) compared with
the patients who were diagnosed with T2DM 9 years earlier
or less (mean value 7.2 × 10−9 cm2, 95% CI: 7.1–7.3, 𝑃 = 0.007).
𝐾
𝑠
and CLT adjusted for fibrinogen and diabetes duration
did not differ between patients with HbA1c >7% and those
with HbA1c ≤7%. In patients with inadequate glucose control
(HbA1c > 7%) we observed similar CLT values compared to
the remainder (mean, 95.9min, 95% CI: 91.0–100.7 versus
94.7min, 95% CI: 91.5–97.9; 𝑃 = 0.69, resp.).
For clot permeability differences between the two groups
were also insignificant (mean, 6.9 × 10−9 cm2, 95%CI: 6.7–7.2,
versus 7.2 × 10−9 cm2, 95% CI: 7.0–7.3; 𝑃 = 0.16, resp.).
Multivariate regression analysis was performed to deter-
mine independent predictors of clot fibrin variables. Analysis
adjusted for fibrinogen, disease duration, and HbA1c showed
that independent predictors of 𝐾
𝑠
in diabetic patients were
nitrotyrosine (𝑃 < 0.001), sRAGE (𝑃 = 0.001), 8-iso-PGF
2𝛼
(𝑃 = 0.003), and oxLDL (𝑃 = 0.01) (Table 4), while oxLDL
(𝑃 < 0.0001) was the only independent predictor of CLT
(Table 5).
4. Discussion
This study is the first to show that enhanced oxidative stress
reflected by its circulating markers including nitrotyrosine,
sRAGE, 8-iso-PGF
2𝛼
, and oxLDL unfavorably affects the
fibrin network structure and susceptibility to lysis in T2DM.
Known factors contributing to the prothrombotic fibrin
clot phenotype observed in patients with diabetes represent
increased plasma fibrinogen concentrations and enhanced
glycation of the fibrinogen or plasminogen molecules [5–
9, 28]. Our observations suggest a novel prothrombotic
mechanism mediated by oxidative stress that may lead to the
formation of denser and resistant to lysis plasma fibrinmesh-
work in T2DM and thus enhancing unfavorable effects of
protein glycation. Moreover, our findings provide additional
evidence that oxidation canmodify the clot structure. In vitro
experiments demonstrated that the extent of oxidation and
substances used to its generation strongly affect alterations
to fibrin clot properties and these effects range widely from
markedly impaired fibrin formation to tendency to produce
compact networks [20]. We found that oxidation superim-
posed on the glycation in diabetes makes fibrin clots less
permeable and poorly lysable.
To assess the impact of oxidation in vivo, we have chosen
five parameters detectable in circulating blood that have been
used in several studies performed in T2DM patients [29, 30].
To our knowledge, associations of these oxidation markers
with fibrin clot characteristics have not been studied yet.
We observed the heterogeneity of the effects of circulating
oxidation markers on fibrin variables in our experimental
approach, which supports the concept that complex oxidative
processes occurring in vivomay alter fibrin clot structure and
function in a different manner.
Measurement of 8-iso-PGF
2𝛼
is a reliable tool for the
identification of subjects with enhanced rates of lipid peroxi-
dation. This prostaglandin is produced by the nonenzymatic
peroxidation of arachidonic acid inmembrane phospholipids
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Table 4: Multivariate regression, dependent variable𝐾
𝑠
.
Independent variables Coefficient Standard error 𝑟partial 𝑡 𝑃
(Constant) 11.49
HbA1c −0.11 0.056 −0.16 −1.90 0.059
DM duration −0.02 0.007 −0.23 −2.77 0.007
Nitrotyrosine, nM/mL −3.66 0.613 −0.45 −5.97 <0.0001
oxLDL, ng/mL −0.002 0.0009 −0.18 −2.11 0.036
Fibrinogen, g/L −0.22 0.0896 −0.21 −2.44 0.016
Method backward, multiple correlation coefficient 0.64; 𝑃 < 0.001.
Abbreviations: see Tables 1 and 2.
Table 5: Multivariate regression, dependent variable CLT.
Independent variables Coefficient Standard error 𝑟partial 𝑡 𝑃
(Constant) 41.05
oxLDL, ng/mL 0.11 0.021 0.41 5.31 <0.001
Fibrinogen, g/L 9.10 2.03 0.36 4.47 <0.001
Method backward, multiple correlation coefficient 0.54; 𝑃 < 0.001.
Abbreviations: see Tables 1 and 2.
[19, 31]. Of special interest are our findings regarding nitroty-
rosine, a product of peroxynitrite action, in the plasma of
diabetic patients. A direct correlation between postprandial
hyperglycemia and the production of nitrotyrosine was
observed in T2DM [32]. There is evidence that peroxynitrite
is generated in diabetes and might be involved in the
development of diabetes complications [33].
We observed that in T2DM patients nitrotyrosine could
be a good predictor of 𝐾
𝑠
. AGEs are modifications of pro-
teins or lipids that become nonenzymatically glycated and
oxidized after contact with aldose sugars. Early glycation and
oxidation processes result in the formation of Schiff bases and
Amadori products. Further glycation of proteins and lipids
causes molecular rearrangements that lead to the generation
of AGEs [34]. Circulating AGE levels are considered a
more accurate biomarker than plasma glucose or HbA1c for
the assessment of cumulative glycemic control [35] and a
major contributor to accelerate both the microvascular and
macrovascular complications in T2DM patients [36].
Activation of RAGE, the receptor for advanced glyca-
tion end products by AGEs, causes upregulation of the
transcription factor nuclear factor-𝜅B and its target genes,
which control cellular expression of RAGE, linking RAGE
to the inflammatory response [37]. Plasma sRAGE correlates
positively with albumin excretion in T2DM patients, which
may represent an early marker of diabetic nephropathy [38].
Some observations suggest the active participation of AGEs-
RAGE axis in accelerated atherosclerosis and development of
diabetic cardiomyopathy via inducing endothelial dysfunc-
tion, inflammatory, fibrotic, and proapoptotic reactions in
the myocardium [39]. Kajikawa et al. reported that the ratio
of AGEs to soluble form of RAGE may be a new chemical
biomarker of endothelial function [40].
However, in our study we observed slight differences in
circulating AGE levels in diabetic patients who had low and
high levels ofHbA1c.We have found that sRAGE alters fibrin-
related prothrombotic mechanisms in T2DM.
A marker of the oxidative modification of LDL particles,
plasma oxidized LDL (oxLDL), is elevated among individuals
with abdominal fat, and it is positively associatedwith T2DM,
fasting glucose, and HbA1c [41]. It has been demonstrated
that oxLDL is an independent risk factor of future clinical
events in a general population [42]. Importantly, oxLDL
was found in the present study as the only independent
predictor of prolonged CLT in T2DM, suggesting that oxLDL
might directly affect the binding of fibrinolysis proteins to
the fibrin fibers and thus impairing plasmin-mediated fibrin
degradation.
Previous studies have demonstrated that oxidative stress
parameters were elevated in patients with long-standing
diabetes [43]. On the other hand, we have shown that
prolonged diabetes duration is linked to persistent prothrom-
botic alterations despite good glycemia control [12].
A role of oxidative stress in maintaining the metabolic
memory has also been suggested [44]. The current study
expands the current knowledge by indicating that oxidative
stress contributes to the fibrin-related aspects of metabolic
memory. We showed that hypofibrinolysis and denser fib-
rin clot networks aggravated by oxidative stress have been
associated with glycemia control and also with prolonged
duration of diabetes. However, diabetes duration itself is the
risk of thrombotic events despite good glycemia control. It is
known that glucose control decreases fibrinogen glycation in
subjects with T2DM. Glycated fibrinogen correlates well with
HbA1c but it does not explain increased blood coagulation in
long-term diabetes and goodmetabolic control of the disease
[45]. It is known that oxidative stress is positively correlated
with glycemic variability over a daily period. It should be
noted that dipeptidyl peptidase-IV (DPP-4) inhibitors can
influence oxidative stress and reduce HbA1c and glycemic
fluctuations on a daily basis [46]. Pharmacological modula-
tion of oxidative stress in diabetes merits further studies in
the context of a prothrombotic state.
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The study has several limitations. First, the size of the
study population was relatively small but representative of
real-life patients with T2DM. Second, we determined each
variable in a single time point, and some changes in the levels
during the follow-up cannot be excluded. Most HbA1c levels
did not exceed 10%, so we did not evaluate patients with
extremely high HbA1c. It should also be noted that duration
of diabetes represents the time from diagnosis, not the actual
duration of the disease. Finally, a large prospective study is
needed to assess the links between the fibrin phenotype in
the context of oxidative stress markers and thromboembolic
events in patients with diabetes.
5. Conclusions
We demonstrated that prothrombotic alterations detectable
in plasma fibrin clot characteristics of T2DM patients are
associated not only with inadequate glycemia control and
disease duration but also with increased oxidation.
Mechanisms behind complex interactions between glyca-
tion and oxidation remain to be established.
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